Major drug breakthrough achieved for Alzheimer

Washington: Treatment for Alzheimer has taken a major step forward, as new drug compound has been found that turns the cognitive discrepancies of the disease.

Researchers from Yale School of Medicine have identified the compound TC-2153, which inhibits the negative effects of a protein called STriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory.

Lead author Paul Lombroso and the co-authors studied thousands of small molecules in mice, searching for those that would inhibit STEP activity and found a reversal of deficits in several cognitive exercises that gauged the animals' ability to remember previously seen objects.

Lombroso said that the small molecule inhibitor was the result of a five-year collaborative effort to search for STEP inhibitors. A single dose of the drug resulted in improved cognitive function in mice. Animals treated with TC compound were indistinguishable from a control group in several cognitive tasks.

The findings are publishing in the journal PLOS Biology. 

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link